Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 637

Similar articles for PubMed (Select 16140944)

1.

Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.

Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, Schrump DS.

Cancer Res. 2005 Sep 1;65(17):7763-74.

2.

Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells.

Kang Y, Hong JA, Chen GA, Nguyen DM, Schrump DS.

Oncogene. 2007 Jun 28;26(30):4394-403. Epub 2007 Jan 29.

PMID:
17260018
3.

Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.

Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H 3rd, Schrump DS, Risinger JI, Barrett JC, Lobanenkov VV.

Cancer Res. 2005 Sep 1;65(17):7751-62.

4.

Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors.

Renaud S, Pugacheva EM, Delgado MD, Braunschweig R, Abdullaev Z, Loukinov D, Benhattar J, Lobanenkov V.

Nucleic Acids Res. 2007;35(21):7372-88. Epub 2007 Oct 25.

5.

Epigenetic regulation of the human retinoblastoma tumor suppressor gene promoter by CTCF.

De La Rosa-Velázquez IA, Rincón-Arano H, Benítez-Bribiesca L, Recillas-Targa F.

Cancer Res. 2007 Mar 15;67(6):2577-85.

6.

Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma.

Sugita M, Geraci M, Gao B, Powell RL, Hirsch FR, Johnson G, Lapadat R, Gabrielson E, Bremnes R, Bunn PA, Franklin WA.

Cancer Res. 2002 Jul 15;62(14):3971-9.

7.

The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer.

Klenova EM, Morse HC 3rd, Ohlsson R, Lobanenkov VV.

Semin Cancer Biol. 2002 Oct;12(5):399-414. Review.

PMID:
12191639
8.

Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.

Loukinov D, Ghochikyan A, Mkrtichyan M, Ichim TE, Lobanenkov VV, Cribbs DH, Agadjanyan MG.

J Cell Biochem. 2006 Aug 1;98(5):1037-43.

PMID:
16741971
9.

Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.

Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, Marincola FM, Fischette MR, Yu X, Chen GA, Hong JA, Stewart JH, Nguyen DM, Rosenberg SA, Schrump DS.

J Immunother. 2001 Mar-Apr;24(2):151-61.

PMID:
11265773
10.

Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.

Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA, Plass C.

J Natl Cancer Inst. 2006 Mar 15;98(6):396-406.

11.

Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylation-sensitive representational difference analysis.

Takai D, Yagi Y, Wakazono K, Ohishi N, Morita Y, Sugimura T, Ushijima T.

Oncogene. 2001 Nov 8;20(51):7505-13.

12.

BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer.

Bhan S, Negi SS, Shao C, Glazer CA, Chuang A, Gaykalova DA, Sun W, Sidransky D, Ha PK, Califano JA.

Clin Cancer Res. 2011 Jul 1;17(13):4267-76. doi: 10.1158/1078-0432.CCR-11-0653. Epub 2011 May 10.

13.

Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1.

Vaughan HA, Svobodova S, Macgregor D, Sturrock S, Jungbluth AA, Browning J, Davis ID, Parente P, Chen YT, Stockert E, St Clair F, Old LJ, Cebon J.

Clin Cancer Res. 2004 Dec 15;10(24):8396-404.

14.

The structural complexity of the human BORIS gene in gametogenesis and cancer.

Pugacheva EM, Suzuki T, Pack SD, Kosaka-Suzuki N, Yoon J, Vostrov AA, Barsov E, Strunnikov AV, Morse HC 3rd, Loukinov D, Lobanenkov V.

PLoS One. 2010 Nov 8;5(11):e13872. doi: 10.1371/journal.pone.0013872.

15.

NY-ESO-1 may be a potential target for lung cancer immunotherapy.

Lee L, Wang RF, Wang X, Mixon A, Johnson BE, Rosenberg SA, Schrump DS.

Cancer J Sci Am. 1999 Jan-Feb;5(1):20-5.

PMID:
10188057
16.

Hypermethylation of the GATA genes in lung cancer.

Guo M, Akiyama Y, House MG, Hooker CM, Heath E, Gabrielson E, Yang SC, Han Y, Baylin SB, Herman JG, Brock MV.

Clin Cancer Res. 2004 Dec 1;10(23):7917-24.

17.

Allele-specific binding of CTCF to the multipartite imprinting control region KvDMR1.

Fitzpatrick GV, Pugacheva EM, Shin JY, Abdullaev Z, Yang Y, Khatod K, Lobanenkov VV, Higgins MJ.

Mol Cell Biol. 2007 Apr;27(7):2636-47. Epub 2007 Jan 22.

18.

NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors.

Sugita Y, Wada H, Fujita S, Nakata T, Sato S, Noguchi Y, Jungbluth AA, Yamaguchi M, Chen YT, Stockert E, Gnjatic S, Williamson B, Scanlan MJ, Ono T, Sakita I, Yasui M, Miyoshi Y, Tamaki Y, Matsuura N, Noguchi S, Old LJ, Nakayama E, Monden M.

Cancer Res. 2004 Mar 15;64(6):2199-204.

19.

Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia.

Paradowska A, Fenic I, Konrad L, Sturm K, Wagenlehner F, Weidner W, Steger K.

Int J Oncol. 2009 Jul;35(1):87-96.

PMID:
19513555
20.

Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues.

Wang XY, Chen HS, Luo S, Zhang HH, Fei R, Cai J.

Oncol Rep. 2009 Mar;21(3):713-9.

PMID:
19212631
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk